1887

Abstract

Introduction:

Ireland currently has the highest reported rate in Europe of vancomycin-resistant (VRE) isolated from the bloodstream, but data regarding the prevalence of VRE endocarditis remain scarce. Treatment options for -mediated endocarditis are limited, and therefore daptomycin is commonly used off licence in this setting.

Case presentation:

A 60-year-old male with end-stage kidney disease (ESKD) presented with VRE bacteraemia secondary to a gangrenous right foot colonized with vancomycin-resistant . Aortic valve endocarditis was confirmed using transoesophageal echocardiography. Treatment was commenced with linezolid and subsequently modified to combination therapy with daptomycin and rifampicin. High-dose daptomycin therapy was employed unsuccessfully and, after 20 days of therapy, daptomycin resistance emerged, which proved fatal.

Conclusion:

The case was ethically challenging and involved a refusal of amputation and, ultimately, any form of treatment by the patient. In summary, however, daptomycin-resistant VRE bacteraemia complicated by recalcitrant daptomycin-resistant VRE endocarditis proved fatal for this patient. Further evaluation of the efficacy and safety of high-dose daptomycin for the treatment of VRE infective endocarditis is needed.

Loading

Article metrics loading...

/content/journal/jmmcr/10.1099/jmmcr.0.000089
2015-10-09
2020-08-13
Loading full text...

Full text loading...

/deliver/fulltext/jmmcr/2/5/jmmcr000089.html?itemId=/content/journal/jmmcr/10.1099/jmmcr.0.000089&mimeType=html&fmt=ahah

References

  1. Biedenbach D. J., Moet G. J., Jones R. N.. 2004; Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis50:59–69 [CrossRef][PubMed]
    [Google Scholar]
  2. Birmingham M. C., Rayner C. R., Meagher A. K., Flavin S. M., Batts D. H., Schentag J. J.. 2003; Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis36:159–168 [CrossRef][PubMed]
    [Google Scholar]
  3. Bishara J., Sagie A., Samra Z., Pitlik S.. 1999; Polymicrobial endocarditis caused by methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococci. Eur J Clin Microbiol Infect Dis18:674–675 [CrossRef][PubMed]
    [Google Scholar]
  4. Boucher H. W., Sakoulas G.. 2007; Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis45:601–608 [CrossRef][PubMed]
    [Google Scholar]
  5. Boucher H. W., Talbot G. H., Bradley J. S., Edwards J. E., Gilbert D., Rice L. B., Scheld M., Spellberg B., Bartlett J.. 2009; Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis48:1–12 [CrossRef][PubMed]
    [Google Scholar]
  6. Carmeli Y., Eliopoulos G., Mozaffari E., Samore M.. 2002; Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med162:2223–2228 [CrossRef][PubMed]
    [Google Scholar]
  7. Cerón I., Muñoz P., Marín M., Segado A., Roda J., Valerio M., Bouza E., Bermejo J., Bouza E., other authors. 2014; Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy. J Antimicrob Chemother69:1669–1674 [CrossRef][PubMed]
    [Google Scholar]
  8. Chuang Y. C., Wang J. T., Lin H. Y., Chang S. C.. 2014; Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis14:687–787 [CrossRef][PubMed]
    [Google Scholar]
  9. Cui L., Tominaga E., Neoh H. M., Hiramatsu K.. 2006; Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother50:1079–1082 [CrossRef][PubMed]
    [Google Scholar]
  10. Cunha B. A., Mickail N., Eisenstein L.. 2007; E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung36:456–461 [CrossRef][PubMed]
    [Google Scholar]
  11. Diaz L., Tran T. T., Munita J. M., Miller W. R., Rincon S., Carvajal L. P., Wollam A., Reyes J., Panesso D., other authors. 2014; Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs. Antimicrob Agents Chemother58:4527–4534 [CrossRef][PubMed]
    [Google Scholar]
  12. DiazGranados C. A., Zimmer S. M., Klein M., Jernigan J. A.. 2005; Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis41:327–333 [CrossRef][PubMed]
    [Google Scholar]
  13. Enoch D. A., Bygott J. M., Daly M. L., Karas J. A.. 2007; Daptomycin. J Infect55:205–213 [CrossRef][PubMed]
    [Google Scholar]
  14. Florescu I., Beuran M., Dimov R., Razbadauskas A., Bochan M., Fichev G., Dukart G., Babinchak T., Cooper C. A., other authors. 2008; Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother62:Suppl 1i17–i28 [CrossRef][PubMed]
    [Google Scholar]
  15. Forrest G. N., Arnold R. S., Gammie J. S., Gilliam B. L.. 2011; Single center experience of a vancomycin resistant enterococcal endocarditis cohort. J Infect63:420–428 [CrossRef][PubMed]
    [Google Scholar]
  16. Hachem R. Y., Hicks K., Huen A., Raad I.. 2003; Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis37:e8–e11 [CrossRef][PubMed]
    [Google Scholar]
  17. Hall A. D., Steed M. E., Arias C. A., Murray B. E., Rybak M. J.. 2012; Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother56:3174–3180 [CrossRef][PubMed]
    [Google Scholar]
  18. Han S. H., Chin B. S., Lee H. S., Jeong S. J., Choi H. K., Kim C. O., Yong D., Choi J. Y., Song Y. G., other authors. 2009; Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. J Infect58:182–190 [CrossRef][PubMed]
    [Google Scholar]
  19. Hawkey P. M.. 2008; Pre-clinical experience with daptomycin. J Antimicrob Chemother62:Suppl 3iii7–iii1418829726
    [Google Scholar]
  20. Humphreys H., Dolan V., Sexton T., Conlon P., Rajan L., Creamer E., Walshe J., Donohoe J., Smyth E. G.. 2004; Implications of colonization of vancomycin-resistant enterococci (VRE) in renal dialysis patients. Learning to live with it?. J Hosp Infect58:28–33 [CrossRef][PubMed]
    [Google Scholar]
  21. Kee S. Y., Park C. W., Lee J. E., Kwon Y. J., Pyo H. J., Kim W. J., Cheong H. J., Western Dialysis Physical Association. 2012; Healthcare-associated risk factors of vancomycin-resistant enterococci colonization among outpatients undergoing hemodialysis. Jpn J Infect Dis65:57–6022274159
    [Google Scholar]
  22. Kelesidis T., Humphries R., Uslan D. Z., Pegues D. A.. 2011; Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis52:228–234 [CrossRef][PubMed]
    [Google Scholar]
  23. Kelley P. G., Gao W., Ward P. B., Howden B. P.. 2011; Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother66:1057–1060 [CrossRef][PubMed]
    [Google Scholar]
  24. Kullar R., Davis S. L., Levine D. P., Zhao J. J., Crank C. W., Segreti J., Sakoulas G., Cosgrove S. E., Rybak M. J.. 2011; High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy31:527–536 [CrossRef][PubMed]
    [Google Scholar]
  25. Kullar R., Casapao A. M., Davis S. L., Levine D. P., Zhao J. J., Crank C. W., Segreti J., Sakoulas G., Cosgrove S. E., Rybak M. J.. 2013; A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother68:2921–2926 [CrossRef][PubMed]
    [Google Scholar]
  26. LaPlante K. L., Rybak M. J.. 2004; Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother48:4665–4672 [CrossRef][PubMed]
    [Google Scholar]
  27. Leclercq R., Bingen E., Su Q. H., Lambert-Zechovski N., Courvalin P., Duval J.. 1991; Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother35:92–98 [CrossRef][PubMed]
    [Google Scholar]
  28. Leither M. D., Shroff G. R., Ding S., Gilbertson D. T., Herzog C. A.. 2013; Long-term survival of dialysis patients with bacterial endocarditis undergoing valvular replacement surgery in the United States. Circulation128:344–351 [CrossRef][PubMed]
    [Google Scholar]
  29. Linden P. K.. 2007; Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med28:632–645 [CrossRef][PubMed]
    [Google Scholar]
  30. Mascio C. T., Alder J. D., Silverman J. A.. 2007; Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother51:4255–4260 [CrossRef][PubMed]
    [Google Scholar]
  31. McDonald J. R., Olaison L., Anderson D. J., Hoen B., Miro J. M., Eykyn S., Abrutyn E., Fowler V. G. Jr, Habib G., other authors. 2005; Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med118:759–766 [CrossRef][PubMed]
    [Google Scholar]
  32. McKinnell J. A., Patel M., Shirley R. M., Kunz D. F., Moser S. A., Baddley J. W.. 2011; Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect139:1342–1350 [CrossRef][PubMed]
    [Google Scholar]
  33. Moise P. A., Hershberger E., Amodio-Groton M. I., Lamp K. C.. 2009; Safety and clinical outcomes when utilizing high-dose ( ≥ 8 mg/kg) daptomycin therapy. Ann Pharmacother43:1211–1219 [CrossRef][PubMed]
    [Google Scholar]
  34. Mylonakis E., Calderwood S. B.. 2001; Infective endocarditis in adults. N Engl J Med345:1318–1330 [CrossRef][PubMed]
    [Google Scholar]
  35. Patel R., Allen S. L., Manahan J. M., Wright A. J., Krom R. A., Wiesner R. H., Persing D. H., Cockerill F. R., Thompson R. L.. 2001; Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl7:27–31 [CrossRef][PubMed]
    [Google Scholar]
  36. Pogue J. M., Paterson D. L., Pasculle A. W., Potoski B. A.. 2007; Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol28:1382–1388 [CrossRef][PubMed]
    [Google Scholar]
  37. Sader H. S., Jones R. N.. 2009; Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis65:158–162 [CrossRef][PubMed]
    [Google Scholar]
  38. Salama N. N., Segal J. H., Churchwell M. D., Patel J. H., Gao L., Heung M., Mueller B. A.. 2009; Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol4:1190–1194 [CrossRef][PubMed]
    [Google Scholar]
  39. Salgado C. D., Farr B. M.. 2003; Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol24:690–698 [CrossRef][PubMed]
    [Google Scholar]
  40. Schulte B., Heininger A., Autenrieth I. B., Wolz C.. 2008; Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidemiol Infect136:1131–1133 [CrossRef][PubMed]
    [Google Scholar]
  41. Schutt A. C., Bohm N. M.. 2009; Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother43:2108–2112 [CrossRef][PubMed]
    [Google Scholar]
  42. Short E., Esterly J., Postelnick M., Ong J., McLaughlin M.. 2014; Disposition of linezolid or daptomycin in enterococcal blood stream infections according to vancomycin resistant Enterococcus colonization. Antimicrob Resist Infect Control3:37–40 [CrossRef][PubMed]
    [Google Scholar]
  43. Steed M. E., Vidaillac C., Rose W. E., Winterfield P., Kaatz G. W., Rybak M. J.. 2011; Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother55:4748–4754 [CrossRef][PubMed]
    [Google Scholar]
  44. Twilla J. D., Finch C. K., Usery J. B., Gelfand M. S., Hudson J. Q., Broyles J. E.. 2012; Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J Hosp Med7:243–248 [CrossRef][PubMed]
    [Google Scholar]
  45. Wisplinghoff H., Bischoff T., Tallent S. M., Seifert H., Wenzel R. P., Edmond M. B.. 2004; Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis39:309–317 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmmcr/10.1099/jmmcr.0.000089
Loading

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error